Medtech Connect Osaka 2022 will bring together Japan’s thriving medtech ecosystem to discuss the future of the Pharmaceutical and Biotechnology industry. In specific we will seek to discuss the challenges in commercialising the newest therapeutics: from cell and gene therapies to regenerative medicine and mRNA. Join us as we explore the future of advanced therapy manufacturing practices, drug delivery, and n of 1 therapies. The challenges to realising next generation therapeutics The race to bring the promise of advanced therapies to Japanese patients.
Date | 10 February 2022
Time | 3:00pm JST/ 2:00pm SGT/ 6:00am GMT
Duration | 2 hours 10 mins
Location | Held online (free)
This event will be broadcast in Japanese and English
Opening remarks | Hironori Kondo, Executive Director and Secretary General, OCCI
Keynote | Engineering the next generation of cell therapies | Matthew Allen, Global Head of Medtech, Cambridge Consultants
Keynote | The challenge of regenerative medicine - Developing new businesses with in-house know-how | Yoichi Honma, Executive Officer & Director of Regenerative Medicine Research Planning Dept., Rohto Pharmaceuticals
Lecture | Synthetic Biology - Current status and future developments | Prof. Akihiko Kondo, Director of Bacchus Bio innovation and Vice President of Kobe University
Japanese Medtech Ecosystem | Lei Liu, Ph.D., Innovation Partnerships & i2.JP Director, AstraZenecaKK
All great innovation networks must have a combination of fearless innovators, visionary investors, and experienced industry players. This session will give an overview of Japan’s medtech innovation ecosystem.
Moderator | Lei Liu, Ph.D., Innovation Partnerships & i2.JP Director, AstraZenecaKK
The challenge to enable next generation therapeutics to reach more patients knows no boundaries. Therefore, Medtech Connect is pleased to host innovators from both within and without Japan to showcase their breakthrough innovations. This year we will highlight 4 companies that are working in the field of next generation therapeutics. To meet the brief the innovation must include a therapeutic breakthrough or an innovation that helps develop or commercialize next generation therapies.
- Joshua Yang, Co-Founder and CEO, Glyphic
- Ben Yellen, CEO, Celldom
- Taku Nakahara, CEO, Metagen Therapeutics
- Shin Hatou, CEO, Cellusion
Special Remark | Buzz Palmer, CEO, The Actuator
The Actuator from Australia will make a special announcement about their future in the Japanese ecosystem.
Panel | Cell & Gene | Advanced Manufacturing
Cell and gene therapies are undeniably a big part of the future of the pharmaceutical and biotechnology industry. The first commercial products are showing astounding clinical benefits to patients but their production is still very challenging to the industry. Join us as we discuss the challenges and the strategies around bringing cell and gene therapies to more patients in APAC.
Moderator – Yan Lin Lye, Head of Medtech APAC, Cambridge Consultants
- Prof. Akihiko Kondo, Director of Bacchus Bio innovation & Vice President of Kobe University
- Michael Paumen, Head of Japan, Pacific Biosciences
- Paulo Garcia, CEO, Kytopen
- Jeffrey Moore, President MP Healthcare Venture Management Inc.
Closing remarks | Simon Karger, Commercial Director Medtech, Cambridge Consultants
Meet the Speakers
This event has now closed